Table 3 Intervals between carboplatin infusion and HD and AUCs of free carboplatin in previous studies of carboplatin-based chemotherapy in HD patients

Kurata et al. (1994) [77]

1

Ovarian carcinoma

240 mg/m² (cycle 1)

1

3.14

240 mg/m² (cycle 2)

2

5.09

Suzuki et al. (1997) [78]

1

Merkel cell carcinoma

150 mg (cycle 1)

1

4.6

150 mg (cycle 2)

2

4.8

Watanabe et al. (2002) [52]

1

Ovarian carcinoma

125 mg (cycle 1)

1.5

2.21

Furuya et al. (2003) [79]

1

Urothelial carcinoma

125 mg

1

2.44

Takezawa et al. (2008) [80]

1

SCLC

250 mg/m² (cycle 1)

1

4.10

275 mg/m² (cycle 2)

1

4.16

Kamata et al. (2009) [81]

1

NSCLC

150 mg/m²

1

4.9

Yoshida et al. (2009) [82]

1

Ovarian carcinoma

125 mg

1

0.98

Kondo et al. (2012) [83]

1

Cancer of unknown primary

125 mg (cycle 1)

1

3.03

125 mg (cycle 2)

1

3.44

125 mg (cycle 3)

1

3.5

Hiraike et al. (2012) [54]

1

SCLC

480 mg (cycle 1)

1

13.45

170 mg (cycle 2)

1

5.74

Motzer et al. (1990) [84]

2

Germ cell tumor

100 mg/m²

24

6.7

Germ cell tumor

100 mg/m²

24

6.9

Chatelut et al. (1994) [48]

1

Ovarian carcinoma

100 mg (cycle 1)

24

3.5

150 mg (cycle 2)

24

6.7

150 mg (cycle 3)

24

6.06

Watanabe et al. (2002) [52]

1

Ovarian carcinoma

125 mg (cycle 2)

16

4.43

125 mg (cycle 3)

16

4.75

125 mg (cycle 4)

16

4.13

Yokoyama et al. (2006) [85]

1

Ovarian carcinoma

200 mg (cycle 1)

24

8.03

200 mg (cycle 2)

16

5.69

Oguri et al. (2010) [51]

2

NSCLC

100 mg

24

4.7

Ovarian cancer

125 mg

24

6.1

Kodama et al. (2010) [86]

1

Ovarian carcinoma

100 mg (cycle 1)

24

3.48

150 mg (cycle 2)

24

4.23

175 mg (cycle 3)

24

5.55

150 mg (cycle 4)

24

4.59